Success Metrics

Clinical Success Rate
91.7%

Based on 11 completed trials

Completion Rate
92%(11/12)
Active Trials
1(8%)
Results Posted
18%(2 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
5
38%
Ph early_phase_1
1
8%
Ph phase_1
1
8%
Ph phase_4
5
38%
Ph phase_2
1
8%

Phase Distribution

2

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
1(7.7%)
Phase 4Post-market surveillance
5(38.5%)
N/ANon-phased studies
5(38.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.7%

11 of 12 finished

Non-Completion Rate

8.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(11)
Terminated(1)

Detailed Status

Completed11
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
1
Success Rate
91.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (7.7%)
Phase 11 (7.7%)
Phase 21 (7.7%)
Phase 45 (38.5%)
N/A5 (38.5%)

Trials by Status

completed1185%
recruiting18%
terminated18%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
DRUG
Total Trials
13